Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (September 2020)
24 slides from Nemaura Medical's investor presentation, Sep 15, 2020
Slide 1: Nemaura Medical
i) NEMAURA MEDICAL Sept 2020
Slide 2: Forward-looking statement
Forward-looking statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1983, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act’), that are subject to risks and uncertainties that co
Slide 3: Key Headlines
Key Headlines Progress aE) ‘CE mark approved and pending FDA approval, proof of concept ‘and product efficacy delivered. Market size: Routes to market: * 450m people with diabetes Distributor agreements (Pwd) globally’ already in place. ‘+ Low market penetration with less than 3m CGM users globally
Slide 4: Investor risks are mitigated
Investor risks are mitigated Technology and Regulatory Proof of product development challenges efficacy mitigation mitigation mitigation CE mark approval The product has to be Studies carried out to obtained as a Class 2b manufacture ready to evidence sugarBEAT? medical device. receive CE approval.
Slide 5: Diabetes a global issue
Diabetes a global issue e Type 1 Type 2 eas doesn’t (Pane Diabetes is a chronic Insulin is a hormone made Not being able to produce insulin or disease that occurs when, by the pancreas, that acts use it effectively leads to raised the pancreas is no longer like a key to let glucose ‘glucose levels i
Slide 6: Diabetes a global issue
Diabetes a global issue pre diabetic adults lol 4. psinennceirm an go ernie CES 191408: Hematol dabets Basan: IF aatees 3tas-om eon 2017 5. ipsivnnidtargabo kiasteinstisaaoeest ace nus We want to: Priority 1 Pal lype 2 diabetes into ¢emission /everse diabetes Priority 2 Help type 1 and type 2 diabet
Slide 7: Long term consequences of diabetes
Long term consequences of diabetes Nerve damage Heart disease Amputation Blindness Stroke Kidney failure « The World Health Organisation estimates that diabetes was the seventh leading cause of death in 20168, « According to the IDF statistics’, every seven seconds someone Is estimated to die from d
Slide 8: The Current CGM offerings
The Current CGM offerings “ pexcom * f Cc) Abbott ‘ 550,000 users i ‘. 2m users ; . (1.1% of Type 1s)® we Tie (496 of Type is)® 2 | | $37Bn $185.4 Bn’ Market Cap Market Cap* www.nemauramedical.com | 08
Slide 9: Why SugarBEAT
Why SugarBEAT® is cheaper Bs Current products primarily serve Type 1 Diabetics who require round the clock monitoring of their blood glucose, SugatBEAT? targets Type 2 Diabetics who do not need to moritor their blood glucose daily but just a few times a week to facilitate litestyle choices following
Slide 10: Global: 450m people with diabetes
Global: 450m The market - People with Diabetes us UK Rest of 30m 3.4me Bee 50m": ‘www.nemauramedical.com | 10
Slide 11: SugarBEAT has the potential to disrupt the global diabetes management market
SugarBEAT” has the potential to disrupt the global diabetes management market We combine SELF MONITORING using the CE Mark approved medical device, SugarBEAT® WEARABLE platform, with one-on-one COACHING (independently clinically proven to enhance the impact of diabetes management) to disrupt the dia
Slide 12: What is the benefit of using SugarBEAT
What is the benefit of using SugarBEAT” SugarBEAT has the potential to help ‘PREVENT’ pre-diabetics from becoming diabetic; there are over 1 Billion pre-diabetics*. Also has the potential to help ‘REVERSE’ Type 2 diabetes; there are over 450 million diabetics of which almost 400 million are Type 2".
Slide 13: What is the benefit of using SugarBEAT
What is the benefit of using SugarBEAT” POWERFUL glucose trend data which gives a direct picture of a person's glucose fluctuations empowering users to make changes to lifestyle and also allowing retrospective therapy adjustment for over 450 million diabetics using the world’s first non-invasive CGM
Slide 14: How SugarBEAT works
How SugarBEAT” works The system Painlesely draws a small The rechargeable Using a proprietary A small transmitter device amount of glucose iranemitter measures algorithm, the App then and an adhesive patch with molecules out of the glucose levels within the displays this data as a sensor sits on top
Slide 15: SugarBEAT technical specification
SugarBEAT” technical specification Real Time Continuous Glucose Monitoring System f: - Non-invasive Sensor ~ Rechargeable Transmitter ~ Proprietary App (Android, 10S) ~ Data is only on Smart Device (GDPR) Functionality: - One glucose measurement every § minutes; data transmitted every 5 minutes via
Slide 16: SugarBEAT - The USP
SugarBEAT® - The USP Non-Invasive a) Painless sensor does not penetrate the skin b) "Peel & Place" sensor Safe | Flexible-use a) CE marking May 2019 Freedom to decide b) MARD 12.4% with 1 calibration/day a) When 6) Absolute & Predictive alerts b) How long d) Insulin dosing decisions with adjunotive
Slide 17: The SugarBEAT Difference
The SugarBEAT® Difference Other players offer either: 1) CGM as a standalone product or 2) Lifestyle behaviour advice through an app We will do BOTH sugarBEAT® sensors and Al using the data to predict, Digital lifestyle Digital coaching transmitter starter pack (CE advice, enhance items 1 behaviour
Slide 18: Who can benefit from SugarBEAT CGM
Who can benefit from SugarBEAT” CGM - everyone 12 T2 Wellness Weight Pre- T2 Diet & VGfalant- >, Long- T2 TH Mgmt Diabetes ” Exercise diabetic acting Intensive drugs Insulins Initial Focus: Non-intensive medical application Wearable Health i Intensive Management ion seca Global Diabetes Market Sear
Slide 19: Routes to market
Routes to market things thé sugar so th hanges and stabil ‘ugar profiles pc venting of fever Type? di The product The device Digital healthcare support Sensors Who will it be sold to: Direct to consumer Corporate clients Healihcare insurers To reduce future costs, insurers who buy subscriptions for
Slide 20: Revenue model
Revenue model www.nemauramedical.com | 20
Slide 21: Commercial strategy - CGM device + subscription based service
Commercial strategy - CGM device + subscription based service Digita VAI Supported by a digital on Creation of Al platform to demand coach enhance user experience (Subscription based) target 3m users. Supported by diabetes / health / nutrition / exercise etc. (Conservative assumption of < 1% of type
Slide 22: Commercial strategy - opportunities at company level
Commercial strategy — opportunities at company level Yo YO & What will be the strategy? Incentives? Working with health insurers? ‘The outcome thus far is evidence For employers the incentive is a more ‘We aim to provide a more holistic based, and this clinical evidence base will be productive work
Slide 23: Our team
Our team The management team Dr. Faz Chowdhury Chief Executive Officer Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013. He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical de
Slide 24: Our team
Our team The management team Dr. Fred Schaebsdau Global Commercial Strategy Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abbog Diabetes Care, where he was a memb
Nemaura Medical — Investor Presentation (September 2020) on 6ix